{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T17:46:58Z","timestamp":1773424018404,"version":"3.50.1"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,8,16]]},"DOI":"10.7759\/cureus.90205","type":"journal-article","created":{"date-parts":[[2025,8,16]],"date-time":"2025-08-16T08:54:11Z","timestamp":1755334451000},"source":"Crossref","is-referenced-by-count":1,"title":["Empagliflozin Treatment for Non-alcoholic Fatty Liver Disease in Type 2 Diabetes Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials"],"prefix":"10.7759","author":[{"given":"Loiy Naser","family":"Alsarkhi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sanjay","family":"Eda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rahman Hameed","family":"Mohammed Abdul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helai","family":"Hussaini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olaniyi","family":"Fadeyi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandipkumar S","family":"Chaudhari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammed Qasim","family":"Rauf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danish","family":"Allahwala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000000004","article-title":"The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review","volume":"77","author":"Younossi ZM","year":"2023","unstructured":"Younossi ZM, Golabi P, Paik JM, Henry A, Van Dongen C, Henry L. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology. 2023, 77:1335-47. 10.1097\/HEP.0000000000000004","journal-title":"Hepatology"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.2337\/dc17-1902","article-title":"Nonalcoholic fatty liver disease and risk of incident type 2 diabetes: a meta-analysis","volume":"41","author":"Mantovani A","year":"2018","unstructured":"Mantovani A, Byrne CD, Bonora E, Targher G. Nonalcoholic fatty liver disease and risk of incident type 2 diabetes: a meta-analysis. Diabetes Care. 2018, 41:372-82. 10.2337\/dc17-1902","journal-title":"Diabetes Care"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases","volume":"67","author":"Chalasani N","year":"2018","unstructured":"Chalasani N, Younossi Z, Lavine JE, et al.. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018, 67:328-57. 10.1002\/hep.29367","journal-title":"Hepatology"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-021-00448-y","article-title":"The complex link between NAFLD and type 2 diabetes mellitus - mechanisms and treatments","volume":"18","author":"Targher G","year":"2021","unstructured":"Targher G, Corey KE, Byrne CD, Roden M. The complex link between NAFLD and type 2 diabetes mellitus - mechanisms and treatments. Nat Rev Gastroenterol Hepatol. 2021, 18:599-612. 10.1038\/s41575-021-00448-y","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1038\/s41581-021-00393-8","article-title":"Pathophysiology of diabetic kidney disease: impact of SGLT2 inhibitors","volume":"17","author":"DeFronzo RA","year":"2021","unstructured":"DeFronzo RA, Reeves WB, Awad AS. Pathophysiology of diabetic kidney disease: impact of SGLT2 inhibitors. Nat Rev Nephrol. 2021, 17:319-34. 10.1038\/s41581-021-00393-8","journal-title":"Nat Rev Nephrol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.2337\/dc19-0641","article-title":"Empagliflozin effectively lowers liver fat content in well-controlled type 2 diabetes: a randomized, double-blind, phase 4, placebo-controlled trial","volume":"43","author":"Kahl S","year":"2020","unstructured":"Kahl S, Gancheva S, Stra\u00dfburger K, et al.. Empagliflozin effectively lowers liver fat content in well-controlled type 2 diabetes: a randomized, double-blind, phase 4, placebo-controlled trial. Diabetes Care. 2020, 43:298-305. 10.2337\/dc19-0641","journal-title":"Diabetes Care"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13520","article-title":"Evaluation of the effects of dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, on hepatic steatosis and fibrosis using transient elastography in patients with type 2 diabetes and non-alcoholic fatty liver disease","volume":"21","author":"Shimizu M","year":"2019","unstructured":"Shimizu M, Suzuki K, Kato K, et al.. Evaluation of the effects of dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, on hepatic steatosis and fibrosis using transient elastography in patients with type 2 diabetes and non-alcoholic fatty liver disease. Diabetes Obes Metab. 2019, 21:285-92. 10.1111\/dom.13520","journal-title":"Diabetes Obes Metab"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2013.05.014","article-title":"Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice","volume":"715","author":"Tahara A","year":"2013","unstructured":"Tahara A, Kurosaki E, Yokono M, et al.. Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice. Eur J Pharmacol. 2013, 715:246-55. 10.1016\/j.ejphar.2013.05.014","journal-title":"Eur J Pharmacol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.2337\/dc18-0165","article-title":"Effect of empagliflozin on liver fat in patients with type 2 diabetes and nonalcoholic fatty liver disease: a randomized controlled trial (E-LIFT trial)","volume":"41","author":"Kuchay MS","year":"2018","unstructured":"Kuchay MS, Krishan S, Mishra SK, et al.. Effect of empagliflozin on liver fat in patients with type 2 diabetes and nonalcoholic fatty liver disease: a randomized controlled trial (E-LIFT trial). Diabetes Care. 2018, 41:1801-8. 10.2337\/dc18-0165","journal-title":"Diabetes Care"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1186\/s13643-016-0259-8","article-title":"Evaluation of the Cochrane tool for assessing risk of bias in randomized clinical trials: overview of published comments and analysis of user practice in Cochrane and non-Cochrane reviews","volume":"5","author":"J\u00f8rgensen L","year":"2016","unstructured":"J\u00f8rgensen L, Paludan-M\u00fcller AS, Laursen DR, et al.. Evaluation of the Cochrane tool for assessing risk of bias in randomized clinical trials: overview of published comments and analysis of user practice in Cochrane and non-Cochrane reviews. Syst Rev. 2016, 5:80. 10.1186\/s13643-016-0259-8","journal-title":"Syst Rev"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-021-01011-3","article-title":"Empagliflozin improves liver steatosis and fibrosis in patients with non-alcoholic fatty liver disease and type 2 diabetes: a randomized, double-blind, placebo-controlled clinical trial","volume":"12","author":"Chehrehgosha H","year":"2021","unstructured":"Chehrehgosha H, Sohrabi MR, Ismail-Beigi F, et al.. Empagliflozin improves liver steatosis and fibrosis in patients with non-alcoholic fatty liver disease and type 2 diabetes: a randomized, double-blind, placebo-controlled clinical trial. Diabetes Ther. 2021, 12:843-61. 10.1007\/s13300-021-01011-3","journal-title":"Diabetes Ther"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.3390\/ph15121516","article-title":"The impact of an SGLT2 inhibitor versus ursodeoxycholic acid on liver steatosis in diabetic patients","volume":"15","author":"Elhini SH","year":"2022","unstructured":"Elhini SH, Wahsh EA, Elberry AA, et al.. The impact of an SGLT2 inhibitor versus ursodeoxycholic acid on liver steatosis in diabetic patients. Pharmaceuticals (Basel). 2022, 15:1516. 10.3390\/ph15121516","journal-title":"Pharmaceuticals (Basel)"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1186\/s12902-025-01882-8","article-title":"The effect of empagliflozin on non-alcoholic fatty liver disease-related parameters in patients with type 2 diabetes mellitus: a randomized controlled trial","volume":"25","author":"Shojaei F","year":"2025","unstructured":"Shojaei F, Erfanifar A, Kalbasi S, Nikpour S, Gachkar L. The effect of empagliflozin on non-alcoholic fatty liver disease-related parameters in patients with type 2 diabetes mellitus: a randomized controlled trial. BMC Endocr Disord. 2025, 25:52. 10.1186\/s12902-025-01882-8","journal-title":"BMC Endocr Disord"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.836455","article-title":"Efficacy and safety of empagliflozin on nonalcoholic fatty liver disease: a systematic review and meta-analysis","volume":"13","author":"Zhang Y","year":"2022","unstructured":"Zhang Y, Liu X, Zhang H, Wang X. Efficacy and safety of empagliflozin on nonalcoholic fatty liver disease: a systematic review and meta-analysis. Front Endocrinol (Lausanne). 2022, 13:836455. 10.3389\/fendo.2022.836455","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2020.105319","article-title":"Effect of sodium-glucose co-transporter 2 inhibitors on hepatic parameters: a systematic review and meta-analysis of randomized controlled trials","volume":"163","author":"Simental-Mend\u00eda M","year":"2021","unstructured":"Simental-Mend\u00eda M, S\u00e1nchez-Garc\u00eda A, Rodr\u00edguez-Ram\u00edrez M, Simental-Mend\u00eda LE. Effect of sodium-glucose co-transporter 2 inhibitors on hepatic parameters: a systematic review and meta-analysis of randomized controlled trials. Pharmacol Res. 2021, 163:105319. 10.1016\/j.phrs.2020.105319","journal-title":"Pharmacol Res"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-017-4370-8","article-title":"SGLT2 inhibitors and risk of cancer in type 2 diabetes: a systematic review and meta-analysis of randomised controlled trials","volume":"60","author":"Tang H","year":"2017","unstructured":"Tang H, Dai Q, Shi W, Zhai S, Song Y, Han J. SGLT2 inhibitors and risk of cancer in type 2 diabetes: a systematic review and meta-analysis of randomised controlled trials. Diabetologia. 2017, 60:1862-72. 10.1007\/s00125-017-4370-8","journal-title":"Diabetologia"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1002\/hep4.1696","article-title":"Ipragliflozin improves the hepatic outcomes of patients with diabetes with NAFLD","volume":"6","author":"Takahashi H","year":"2022","unstructured":"Takahashi H, Kessoku T, Kawanaka M, et al.. Ipragliflozin improves the hepatic outcomes of patients with diabetes with NAFLD. Hepatol Commun. 2022, 6:120-32. 10.1002\/hep4.1696","journal-title":"Hepatol Commun"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2017.05.028","article-title":"SGLT2 inhibition by empagliflozin promotes fat utilization and browning and attenuates inflammation and insulin resistance by polarizing M2 macrophages in diet-induced obese mice","volume":"20","author":"Xu L","year":"2017","unstructured":"Xu L, Nagata N, Nagashimada M, et al.. SGLT2 inhibition by empagliflozin promotes fat utilization and browning and attenuates inflammation and insulin resistance by polarizing M2 macrophages in diet-induced obese mice. EBioMedicine. 2017, 20:137-49. 10.1016\/j.ebiom.2017.05.028","journal-title":"EBioMedicine"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink HJ","year":"2020","unstructured":"Heerspink HJ, Stef\u00e1nsson BV, Correa-Rotter R, et al.. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020, 383:1436-46. 10.1056\/NEJMoa2024816","journal-title":"N Engl J Med"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13584","article-title":"Effect of canagliflozin treatment on hepatic triglyceride content and glucose metabolism in patients with type 2 diabetes","volume":"21","author":"Cusi K","year":"2019","unstructured":"Cusi K, Bril F, Barb D, et al.. Effect of canagliflozin treatment on hepatic triglyceride content and glucose metabolism in patients with type 2 diabetes. Diabetes Obes Metab. 2019, 21:812-21. 10.1111\/dom.13584","journal-title":"Diabetes Obes Metab"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.2337\/dc16-0330","article-title":"CV protection in the EMPA-REG OUTCOME trial: a \"thrifty substrate\" hypothesis","volume":"39","author":"Ferrannini E","year":"2016","unstructured":"Ferrannini E, Mark M, Mayoux E. CV protection in the EMPA-REG OUTCOME trial: a \"thrifty substrate\" hypothesis. Diabetes Care. 2016, 39:1108-14. 10.2337\/dc16-0330","journal-title":"Diabetes Care"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins JP","year":"2003","unstructured":"Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003, 327:557-60. 10.1136\/bmj.327.7414.557","journal-title":"BMJ"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.2337\/dc16-1787","article-title":"Management of nonalcoholic fatty liver disease in patients with type 2 diabetes: a call to action","volume":"40","author":"Bril F","year":"2017","unstructured":"Bril F, Cusi K. Management of nonalcoholic fatty liver disease in patients with type 2 diabetes: a call to action. Diabetes Care. 2017, 40:419-30. 10.2337\/dc16-1787","journal-title":"Diabetes Care"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2020-322572","article-title":"Non-alcoholic fatty liver disease and risk of incident diabetes mellitus: an updated meta-analysis of 501022 adult individuals","volume":"70","author":"Mantovani A","year":"2021","unstructured":"Mantovani A, Petracca G, Beatrice G, Tilg H, Byrne CD, Targher G. Non-alcoholic fatty liver disease and risk of incident diabetes mellitus: an updated meta-analysis of 501022 adult individuals. Gut. 2021, 70:962-9. 10.1136\/gutjnl-2020-322572","journal-title":"Gut"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)30474-4","article-title":"NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial","volume":"391","author":"Harrison SA","year":"2018","unstructured":"Harrison SA, Rinella ME, Abdelmalek MF, et al.. NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet. 2018, 391:1174-85. 10.1016\/S0140-6736(18)30474-4","journal-title":"Lancet"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/399149-empagliflozin-treatment-for-non-alcoholic-fatty-liver-disease-in-type-2-diabetes-patients-a-systematic-review-and-meta-analysis-of-randomized-controlled-trials","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,16]],"date-time":"2025-08-16T08:54:11Z","timestamp":1755334451000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/399149-empagliflozin-treatment-for-non-alcoholic-fatty-liver-disease-in-type-2-diabetes-patients-a-systematic-review-and-meta-analysis-of-randomized-controlled-trials"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,16]]},"references-count":25,"URL":"https:\/\/doi.org\/10.7759\/cureus.90205","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8,16]]}}}